EU/3/07/472

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2012 on request of the sponsor.

On 14 September 2007, orphan designation (EU/3/07/472) was granted by the European Commission to Lux Biosciences GmbH, Germany, for cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl} for the treatment of chronic non-infectious uveitis.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}
Disease / condition
Treatment of chronic non-infectious uveitis
Date of first decision
14/09/2007
Outcome
Withdrawn
EU designation number
EU/3/07/472

Sponsor's contact details

Lux Biosciences GmbH
Dreieichstr. 59
D-60594 Frankfurt am Main
Germany
Tel. + 49 69 5050 65 991
Fax + 49 69 5050 65 980
E-mail: info@luxbio.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating